Shares of Capricor Therapeutics Inc. nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat results from a trial for its treatment (CAP-1002) of Duchenne muscular dystrophy. Trading volume was about 1.7 million shares ahead of the open, compared with the full-day average of about 56,500 shares. "I am incredibly pleased with the outcome of the interim analysis as it has demonstrated the biologic activity of CAP-1002 that has resulted in changes of clinically relevant outcomes including the upper limb, the hand and diaphragmatic function," said Craig McDonald, the principal investigator for the trial. The stock has lost 42.6% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has slipped 4.5% and the S&P 500 has gained 3.7%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.